{
    "b1eedb1d-8551-3bc0-aba1-3b4e5cc28b6a": {
        "uuid": "b1eedb1d-8551-3bc0-aba1-3b4e5cc28b6a",
        "title": "The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ\u00ae) in Ulcerative Colitis",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/lancet-publishes-results-phase-3-071500315.html",
        "providerPublishTime": 1653635700,
        "type": "STORY"
    },
    "9d2fda01-507a-3e35-9a14-0c01d2665d9a": {
        "uuid": "9d2fda01-507a-3e35-9a14-0c01d2665d9a",
        "title": "The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI\u00ae) in Crohn's Disease",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/lancet-publishes-results-phase-3-070000423.html",
        "providerPublishTime": 1653634800,
        "type": "STORY"
    },
    "077348f9-154c-30c0-827c-63f53b34702c": {
        "uuid": "077348f9-154c-30c0-827c-63f53b34702c",
        "title": "AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed",
        "publisher": "TheStreet.com",
        "link": "https://finance.yahoo.com/m/077348f9-154c-30c0-827c-63f53b34702c/abbvie%27s-correction-appears.html",
        "providerPublishTime": 1653589140,
        "type": "STORY"
    },
    "2ba77cb7-8b04-3d5a-b01c-065ea14eaacd": {
        "uuid": "2ba77cb7-8b04-3d5a-b01c-065ea14eaacd",
        "title": "Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/amgen-amgn-ahead-industry-far-115111980.html",
        "providerPublishTime": 1653565871,
        "type": "STORY"
    },
    "679f570f-a870-3ef1-a644-6eaeeb20231f": {
        "uuid": "679f570f-a870-3ef1-a644-6eaeeb20231f",
        "title": "3 Healthcare Stocks You Can Buy and Hold for the Next Decade",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/679f570f-a870-3ef1-a644-6eaeeb20231f/3-healthcare-stocks-you-can.html",
        "providerPublishTime": 1653559200,
        "type": "STORY"
    },
    "cc8420fe-01f8-3e0b-85b4-85ff830fff37": {
        "uuid": "cc8420fe-01f8-3e0b-85b4-85ff830fff37",
        "title": "Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?",
        "publisher": "Investor's Business Daily",
        "link": "https://finance.yahoo.com/m/cc8420fe-01f8-3e0b-85b4-85ff830fff37/is-abbvie-stock-a-buy-as.html",
        "providerPublishTime": 1653499875,
        "type": "STORY"
    },
    "148c0a67-9152-3dc6-8dcd-6e0216574877": {
        "uuid": "148c0a67-9152-3dc6-8dcd-6e0216574877",
        "title": "SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/springworks-swtx-down-despite-desmoid-160504171.html",
        "providerPublishTime": 1653494704,
        "type": "STORY"
    },
    "16b7a6f8-68d6-3c27-9b25-218bb2e67827": {
        "uuid": "16b7a6f8-68d6-3c27-9b25-218bb2e67827",
        "title": "2 Dividend Kings That Are Soundly Beating the Market in 2022",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/16b7a6f8-68d6-3c27-9b25-218bb2e67827/2-dividend-kings-that-are.html",
        "providerPublishTime": 1653490800,
        "type": "STORY"
    }
}